Pract Radiat Oncol. 2026 Nov 14:S1879-8500(26)00352-8. doi: 10.1016/j.prro.2026.11.010. Online ahead of print.
ABSTRACT
PURPOSE: Prostate stereotactic body radiation therapy (SBRT) on a 1.5-T magnetic resonance imaging (MRI) linear accelerator (MR-linac) combines high-contrast intrafraction imaging with online adaptive replanning and enables focal dose intensification. Patients with cardiac implantable electronic devices (CIEDs) nonetheless face barriers to MR-guided radiotherapy (MRgRT), because existing guidance addresses diagnostic MRI and radiotherapy exposures separately and does not specify fraction-level requirements for their combination. We developed and implemented a framework integrating both domains in one operational pathway.
METHODS: A multidisciplinary group synthesized diagnostic MRI, radiotherapy, and MR-linac safety evidence into a dual-axis risk model. The MRI/CIED axis is keyed to device exposure (generator-lead configuration, manufacturer conditions, and sequence-level radiofrequency and gradient compliance) rather than anatomic field of view. The radiotherapy (RT)/CIED axis stratifies neutron production, cumulative generator dose, generator-to-field geometry, and pacing dependence. A failure mode and effects analysis translated high-priority scenarios into hold points and role assignments; the pathway is implemented prospectively for CIED patients on a 1.5-T MR-linac.
RESULTS: The two axes intersect in a matrix assigning every patient to one of six classes: LOW, LOW/INTERMEDIATE, INTERMEDIATE, INTERMEDIATE/HIGH, HIGH, or HOLD. Each class specifies monitoring, consent, interrogation, programming, personnel, and platform requirements. These are implemented through a day-of-treatment workflow with named role ownership and sequential hold points aligned with the 2026 American College of Radiology Manual on MR Safety. Two determinations override the matrix: MR-hold defers MRgRT irrespective of radiotherapy category, and RT-high defaults to computed tomography-guided radiotherapy.
CONCLUSIONS: By unifying MRI- and radiotherapy-specific device risks, the dual-axis framework converts categorical CIED exclusion into a graded, prospectively assigned disposition and makes every decision auditable. It is in prospective clinical use and offers appropriately selected patients a conservative route to MRgRT and the documentation from which multi-institutional validation can be built.
PMID:43033910 | DOI:10.1016/j.prro.2026.11.010